drugset / Trial / NCT02399189
MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of chemotherapy with MT-R followed by autologous stem cells transplantation in newly-diagnosed primary central nervous system lymphoma.
Timeline
- Start
- 2014-05
- Primary completion
- 2017-04
- Completion
- 2019-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methotrexate | Small molecule | 3.5 g | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Subject | Temozolomide | Small molecule | 100 mg/m2 | — |
| Subject | Thiotepa | Other / unclassified | 5 mg/kg | — |
| Subject | carmustine | Small molecule | 400 mg/m2 | — |